Literature DB >> 21833949

Antibiotics for preventing meningococcal infections.

Anca Zalmanovici Trestioreanu1, Abigail Fraser, Anat Gafter-Gvili, Mical Paul, Leonard Leibovici.   

Abstract

BACKGROUND: Meningococcal disease is a contagious bacterial infection caused by Neisseria meningitidis (N. meningitidis). Household contacts have the highest risk of contracting the disease during the first week of a case being detected. Prophylaxis is considered for close contacts of people with a meningococcal infection and populations with known high carriage rates.
OBJECTIVES: To study the effectiveness of different prophylactic treatment regimens. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 2) which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE (January 1966 to May Week 3, 2011), EMBASE (1980 to May 2011) and LILACS (1982 to May 2011). SELECTION CRITERIA: Randomised controlled trials (RCTs) or quasi-RCTs addressing the effectiveness of different antibiotics for: (a) prophylaxis against meningococcal disease; (b) eradication of N. meningitidis. DATA COLLECTION AND ANALYSIS: Two review authors independently appraised the quality and extracted data from the included trials. We analysed dichotomous data by calculating the risk ratio (RR) and 95% confidence interval (CI) for each trial. MAIN
RESULTS: We included 24 studies; 19 including 2531 randomised participants and five including 4354 cluster-randomised participants. There were no cases of meningococcal disease during follow up in the trials, thus effectiveness regarding prevention of future disease cannot be directly assessed.Ciprofloxacin (RR 0.04; 95% CI 0.01 to 0.12), rifampin (rifampicin) (RR 0.17; 95% CI 0.13 to 0.24), minocycline (RR 0.28; 95% CI 0.21 to 0.37) and penicillin (RR 0.47; 95% CI 0.24 to 0.94) proved effective at eradicating N. meningitidis one week after treatment when compared with placebo. Rifampin (RR 0.20; 95% CI 0.14 to 0.29), ciprofloxacin (RR 0.03; 95% CI 0.00 to 0.42) and penicillin (RR 0.63; 95% CI 0.51 to 0.79) still proved effective at one to two weeks. Rifampin was effective compared to placebo up to four weeks after treatment but resistant isolates were seen following prophylactic treatment. No trials evaluated ceftriaxone against placebo but ceftriaxone was more effective than rifampin after one to two weeks of follow up (RR 5.93; 95% CI 1.22 to 28.68). Mild adverse events associated with treatment were observed. AUTHORS'
CONCLUSIONS: Using rifampin during an outbreak may lead to the circulation of resistant isolates. Use of ciprofloxacin, ceftriaxone or penicillin should be considered. All four agents were effective for up to two weeks follow up, though more trials comparing the effectiveness of these agents for eradicating N. meningitidis would provide important insights.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833949     DOI: 10.1002/14651858.CD004785.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  8 in total

1.  Arr-cb Is a Rifampin Resistance Determinant Found Active or Cryptic in Clostridium bolteae Strains.

Authors:  Jean-Christophe Marvaud; Thierry Lambert
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.

Authors:  Eva Hong; Sara Thulin Hedberg; Raquel Abad; Cecilia Fazio; Rocío Enríquez; Ala-Eddine Deghmane; Keith A Jolley; Paola Stefanelli; Magnus Unemo; Julio A Vazquez; Frédéric J Veyrier; Muhamed-Kheir Taha
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

3.  Management of a rifampicin-resistant meningococcal infection in a teenager.

Authors:  D Delaune; D Andriamanantena; A Mérens; E Viant; O Aoun; F Ceppa; M-K Taha; C Rapp
Journal:  Infection       Date:  2013-02-14       Impact factor: 3.553

Review 4.  Antibiotics for preventing meningococcal infections.

Authors:  Anca Zalmanovici Trestioreanu; Abigail Fraser; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-25

5.  Shifts in the Antibiotic Susceptibility, Serogroups, and Clonal Complexes of Neisseria meningitidis in Shanghai, China: A Time Trend Analysis of the Pre-Quinolone and Quinolone Eras.

Authors:  Mingliang Chen; Qinglan Guo; Ye Wang; Ying Zou; Gangyi Wang; Xi Zhang; Xiaogang Xu; Miao Zhao; Fupin Hu; Di Qu; Min Chen; Minggui Wang
Journal:  PLoS Med       Date:  2015-06-09       Impact factor: 11.069

Review 6.  Meningococcal Vaccinations.

Authors:  Nancy Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2016-04-16

7.  Characterization, activity, and computer modeling of a molecular inclusion complex containing rifaldazine.

Authors:  Qunyou Tan; Dan He; Mingjun Wu; Lin Yang; Yong Ren; Juan Liu; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2013-02-01

8.  Evolutionary analysis of gyrA gene from Neisseria meningitidis bacterial strains of clonal complex 4821 collected in China between 1978 and 2016.

Authors:  Pan Zhao; Li Xu; Aiyu Zhang; Bingqing Zhu; Zhujun Shao
Journal:  BMC Microbiol       Date:  2020-03-30       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.